Streptococcus pneumoniae (the pneumococcus) is a major cause of mortality and morbidity globally, and the leading cause of death in children under 5 years old. The pneumococcal cytolysin pneumolysin (PLY) is a major virulence determinant known to induce pore-dependent pro-inflammatory responses. These inflammatory responses are driven by PLY-host cell membrane cholesterol interactions, but binding to a host cell receptor has not been previously demonstrated. Here, we discovered a receptor for PLY, whereby pro-inflammatory cytokine responses and Toll-like receptor signalling are inhibited following PLY binding to the mannose receptor C type 1 (MRC-1) in human dendritic cells and mouse alveolar macrophages. The cytokine suppressor SOCS1 is also upregulated. Moreover, PLY-MRC-1 interactions mediate pneumococcal internalization into non-lysosomal compartments and polarize naive T cells into an interferon-γ low , interleukin-4 high and FoxP3 + immunoregulatory phenotype. In mice, PLY-expressing pneumococci colocalize with MRC-1 in alveolar macrophages, induce lower pro-inflammatory cytokine responses and reduce neutrophil infiltration compared with a PLY mutant. In vivo, reduced bacterial loads occur in the airways of MRC-1-deficient mice and in mice in which MRC-1 is inhibited using blocking antibodies. In conclusion, we show that pneumococci use PLY-MRC-1 interactions to downregulate inflammation and enhance bacterial survival in the airways. These findings have important implications for future vaccine design.
is released during bacterial autolysis, but has also been shown to be localized on the pneumococcal cell wall, thereby becoming accessible to extracellular proteases 8 . The surface localization of PLY leads one to speculate that there is a non-cholesterol receptor on host cells.
Alveolar macrophages and dendritic cells (DCs) are the major resident immune cells in alveoli and mediate protection from pathogens. The mannose receptor MRC-1 (also known as CD206) is an M2 phenotype marker 9 and a phagocytic receptor 10 that is mostly expressed by tissue macrophages, including alveolar macrophages 11 . MRC-1 binds to endogenous and microbial antigens such as capsular polysaccharides 12, 13 . Furthermore, studies have demonstrated that MRC-1 influences pneumococcal uptake by Schwann and olfactory cells, but they did not show colocalization 14, 15 . It is not clear which macrophage receptors recognize pneumococci in the nasopharynx and lungs and what bacterial properties interact with the receptors mediating pneumococcal uptake. Here, we discovered a role for PLY in driving anti-inflammatory responses and lysosomal escape in macrophages and DCs by directly binding to MRC-1, thereby promoting pneumococcal internalization and survival in the host.
We first compared the cytokine response induced by PLY by infecting different immune cells-primary human monocytederived DCs, neutrophils and THP-1 monocyte-derived macrophages-with a low dose (multiplicity of infection (MOI) of 1) of the pneumococcal strain T4R (which expresses PLY) or its isogenic PLY mutant T4R∆ ply. The non-encapsulated strain T4R (an isogenic capsular mutant of the encapsulated serotype 4 strain T4) was used for the in vitro experiments to increase bacterial uptake since the capsule impedes bacterial adhesion to host cells 16 . We found lower secretion of the pro-inflammatory cytokines tumour necrosis factor-α (TNF-α ), interleukin-1β (IL-1β ) and IL-12 from DCs challenged with PLY-proficient T4R compared with the mutant T4R∆ ply, which was in contrast to THP-1-derived macrophages and neutrophils ( Fig. 1a ; Supplementary Fig. 1 a,b ). This PLY-dependent inhibition of cytokine responses was also observed Letters NaTuRe MICRObIOLOgY using the encapsulated strains T4 and T4∆ ply (Fig. 1b) . The cytokine inhibition was independent of cell death, as determined by measuring lactate dehydrogenase release ( Supplementary Fig. 1c ), but dependent on bacterial uptake since secretion of TNF-α was reduced after phagocytosis was blocked using cytochalasin D and wortmannin ( Supplementary Fig. 1d ). Treatment with cytochalasin D, an inhibitor of actin polymerization, inhibited cytokine production by DCs and THP-1 macrophages in a PLY-independent manner. Pretreatment with purified endotoxin-free PLY at 100 ng ml -1 inhibited IL-12 production by ~50% from DCs infected with T4R∆ ply in a dose-dependent manner, independent of cell death ( Supplementary Fig. 1e ). We then further studied the effect of using different pneumococcal strains and challenge doses. We infected DCs, THP-1 macrophages, neutrophils and bone-marrowderived macrophages (BMDMs) with the pneumococcal strain D39 of serotype 2 or its isogenic PLY mutant, D39Δ ply, at different MOIs and measured IL-1β release and cell death ( Supplementary  Fig. 1f-i ). We observed that at lower infection doses (MOI of 0.1 or 1), the mutant D39Δ ply induced higher levels of IL-1β release in DCs and BMDMs (but not in neutrophils or THP-1 macrophages) independent of cell death. However, at a MOI of 10, the pattern was reversed, and wild-type D39 induced higher IL-1β release, but this was also accompanied by an approximately twofold higher rate of cell death.
We then performed a Toll-like receptor (TLR) signalling quantitative PCR (qPCR) array using RNA from DCs infected for 9 h with T4R or T4R∆ ply. Expression of all genes, except IFNB1 (encoding IFN-β 1), was upregulated following infection with T4RΔ ply compared with T4R-infected cells ( Supplementary Fig. 1j ). This result indicated that PLY expression has a general inhibitory effect on cytokine induction and inflammatory signalling in DCs.
To explore the mechanisms behind this inhibitory effect of PLY on DCs, we measured the expression of the negative regulators of nuclear factor-κ B (NF-κ B), AP-1 (activator protein 1 ) and STAT1 (signal transducer and activator of transcription 1) pro-inflammatory signalling pathways. We identified that suppressor of cytokine signalling 1 (SOCS1) 17 mRNA was upregulated in DCs infected with T4R, but not with T4R∆ ply (Fig. 1c) . A kinetic analysis revealed that SOCS1 mRNA increased 6 h post infection and peaked at 9 h ( Supplementary Fig. 1k ). Concurrent with the mRNA result, the protein levels of SOCS1 were higher in DCs at 9 h post infection with T4R compared with T4R∆ ply (Fig. 1d ). However, SOCS1 expression remained unaffected in THP-1 macrophages ( Supplementary  Fig. 1l ), confirming the cell-type-specific effect.
Since SOCS1 is a known inhibitor of STAT signalling 18 , we measured the levels of phosphorylated STAT1 and found that phosphorylation in T4R-infected DCs was delayed compared with T4RΔ ply (Fig. 1e ). Pretreatment with the STAT inhibitor stattic inhibited the secretion of TNF-α , IL-1β and IL-12 ( Supplementary Fig. 1m-o) . In addition to STAT1, we found lower levels of NF-κ B in T4Rinfected DCs compared with T4RΔ ply (Fig. 1f ). Together, our data suggest that PLY expression inhibits pro-inflammatory signalling via STAT1 and NF-κ B in DCs, possibly via the induction of the cytokine suppressor SOCS1. 
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To identify the host receptor interacting with PLY, we performed a pull-down assay using purified PLY. Thirty-two proteins were identified exclusively in DC lysates, and three of these proteins were surface proteins: integrin alpha M, MRC-1 and galectin 1 ( Supplementary Table 1 ). We further investigated the lectin receptor MRC-1, since it has previously been reported to have immunosuppressive properties 19 . To confirm the interaction between MRC-1 and PLY, we performed immunoprecipitation of MRC-1 from native DC lysates using anti-PLY coupled beads ( Supplementary Fig. 2a ). To assess whether the binding of MRC-1 to PLY was mediated via glycan recognition, we performed enzymatic deglycosylation of PLY to remove bound glycans, which would be evidenced by the slightly higher electrophoretic gel mobility ( Supplementary Fig. 2b ). Importantly, MRC-1 co-immunoprecipitated with both native and deglycosylated PLY from native DC lysates ( Supplementary  Fig. 2c ). We found that MRC-1 was selectively expressed by DCs and macrophage colony stimulating factor (M-CSF)-derived macrophages (M2 polarized), but not by THP-1 macrophages, neutrophils or granulocyte-macrophage colony-stimulating factor (GM-CSF)-derived macrophages (M1 polarized) ( Supplementary  Fig. 2d -e). Interestingly, DCs exhibited an upregulated expression of MRC-1 following infection with T4R compared with T4RΔ ply ( Supplementary Fig. 2f ). Similar to human DCs, BMDMs isolated from wild-type, but not MRC1 −/− , mice exhibited an upregulation in the production of MRC-1 protein following infection with strain D39 compared with its isogenic PLY-deficient mutant D39Δ ply ( Supplementary Fig. 2g ). The capsular mutant (D39Δ cps) induced a lower upregulation of MRC-1 expression than D39 ( Supplementary  Fig. 2h ). An analysis of MRC-1 expression at different MOI values revealed that DCs and BMDMs upregulated MRC-1 expression in a dose-dependent way in response to D39 compared with D39Δ ply, and the difference was significant at an MOI of 1 ( Supplementary  Fig. 2i -l). Neutrophils and THP-1 macrophages showed very low MRC-1 expression, which did not change significantly following infection. A surface plasmon resonance analysis confirmed the PLY-MRC-1 interaction, showing a dissociation constant (K d ) value of 4.5 × 10 −8 M (Fig. 2a ). The interaction was also verified in the reverse orientation ( Supplementary Fig. 2m ), and the specificity was shown using control proteins ( Supplementary Fig. 2n ). To study the specific interaction of MRC-1 with PLY versus capsular polysaccharides, we performed an ELISA assay to measure the dose-dependent binding of PLY to immobilized MRC-1 in the presence or absence of purified serotype 2 or 4 capsules. We found that MRC-1 bound to the type 2 but not the type 4 capsule ( Supplementary Fig. 2o ). Importantly, MRC-1 still bound to PLY even in the presence of the capsule, albeit to a lesser extent ( Supplementary Fig. 2o ). To identify the region of interaction, we performed a solid-phase binding assay using purified PLY domains and a construct containing the Fc fragment and the mannose-binding C-type lectin-like carbohydrate recognition domains of MRC-1 (CTLD4-7-Fc). We found that domain 4 of PLY is key to the MRC-1-PLY-interaction, as purified domain 4 but not domains 1-3 bound the CTLD4-7-Fc construct ( Fig. 2b) . The non-pore-forming PLY mutant (PdB) 20 showed reduced binding compared with cytolytic PLY (Fig. 2b) , indicating that active PLY is required for MRC-1 binding.
Next, we investigated the localization patterns of MRC-1 and PLY in DCs using immunofluorescence microscopy. Wild-type DCs or MRC-1-deficient DCs (treated with short interfering RNA (siRNA) against MRC1), were incubated for 45 min with recombinant active PLY. PLY colocalized with MRC-1 and the early endosomal antigen EEA-1, indicating uptake by DCs ( Fig. 2c ). In contrast, PLY binding was reduced in MRC-1-deficient DCs. In addition, the non-pore-forming PLY mutant (PdB) did not colocalize with MRC-1 ( Fig. 2c ). At 90 min post pneumococcal challenge, internalized T4R colocalized with MRC-1, but did not colocalize with lysosomes, while the converse was observed for T4RΔ ply (Fig. 2d ). To test whether bacterial internalization via MRC-1 inhibits the fusion of pneumococcal-infected vacuoles with lysosomes, we used antibody-opsonized pneumococci as a control to engage Fc gamma receptor-mediated phagocytosis 21 . Strikingly, opsonized T4 did not colocalize with MRC-1 and co-stained with lysosomes in contrast to the non-opsonized control ( Supplementary Fig. 2p ). Moreover, opsonized T4 elicited similar levels of TNF-α and IL-1β release from DCs as T4∆ ply ( Supplementary Fig. 2q ). To explore whether active PLY is required for interactions with MRC-1 in clinical pneumococcal isolates, we used a serotype 1 strain expressing non-haemolytic PLY (BHN31 of ST306) and the clonally related haemolytic strain (BHN32 of ST228) 22 . We found that the nonhaemolytic strain did not colocalize with MRC-1, but co-stained for lysosomes ( Supplementary Fig. 2r ) and elicited higher cytokine production from DCs ( Supplementary Fig. 2s ) compared with the haemolytic strain. Together, our data suggest that pneumococcal internalization, due to interactions between active PLY and MRC-1, inhibits the fusion of vacuoles containing pneumococci with lysosomes. This is supported by previous findings that MRC-1 regulates phagosomal trafficking following phagocytosis and limits fusion with lysosomes 10, 23 .
Furthermore, we found that uptake of PLY-proficient T4R, but not T4R∆ ply, was reduced by 50% in MRC-1-depleted DCs ( Fig. 3a ; Supplementary Fig. 3a ). Also, depletion of MRC-1 in DCs led to significantly higher levels of IL-12, TNF-α and IL-6 following T4R infection (Fig. 3b ), and abrogated SOCS1 expression ( Supplementary Fig. 3b ). This suggests that activation of MRC-1 by PLY triggers an upregulation of SOCS1 in DCs, thereby reducing the secretion of inflammatory cytokines.
Since DCs are professional antigen-presenting cells, we investigated the role of MRC-1 in DC-primed CD4 + T helper cell cytokine responses after pneumococcal challenge. In contrast to T4RΔ ply-infected cells, we found that DCs depleted of MRC1 using siRNA and infected with T4R elicited higher IFN-γ (a T helper type 1 cytokine) and lower IL-4 (T helper type 2 cytokine) levels from naive T helper cells in co-culture compared with DCs treated with control siRNA (Fig. 3c,d ). A similar trend was observed in DCs stimulated with purified PLY. To further characterize the phenotype of T cells co-cultured with DCs, we measured FoxP3, a regulatory T cell marker 24 , and found that DCs infected with T4R (but not with T4RΔ ply) and those treated with purified PLY induced higher FoxP3 expression in naive T helper cells after co-culture ( Fig. 3e ; Supplementary Fig. 3c ). FoxP3 upregulation in T cells was abolished when co-cultured with DCs treated with MRC1 siRNA. Similar to human DCs, mouse BMDMs from wild-type mice that were infected with D39 (in contrast to D39Δ ply) and co-cultured with CD4 + mouse T cells resulted in higher regulatory (expressing FoxP3 and IL-10) T cells and lower T helper type 1 cells (expressing T-bet and IFN-γ ) compared to BMDMs from MRC1 −/− mice ( Fig. 3f ; Supplementary Fig. 3d-f ). Our data are in agreement with earlier findings showing that MRC-1 expression in DCs inhibits CD45 and induces T cell tolerance 25 , and that PLY is required for robust regulatory T cell induction by pneumococci in vivo 26 .
To verify our findings in vivo, we challenged wild-type C57BL/6J mice intranasally with 1 × 10 6 colony-forming units (CFU) of wildtype T4 or the mutant T4Δ ply. At 6 h post infection, bronchoalveolar lavage fluid (BALF) was collected and lung alveolar macrophages isolated. We observed intracellular colocalization of strain T4 with MRC-1, but not with lysosomes ( Fig. 4a ). In contrast, intracellular T4Δ ply did not colocalize with MRC-1, but co-stained with lysosomes ( Fig. 4a, Supplementary Fig. 4a ). Ex vivo, mouse alveolar macrophages secreted lower levels of pro-inflammatory cytokines following infection with T4R compared with T4RΔ ply. This difference was reduced by pretreatment with an anti-MRC-1 antibody ( Supplementary Fig. 4b,c ). In agreement with these results, T4Δ ply-infected mice had higher levels of pro-inflammatory cytokines, 
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TNF-α , IL-12 and IL-1β , and lower levels of anti-inflammatory cytokines, IL-10 and transforming growth factor-β (TGF-β ), in the BALF compared with mice infected with T4 ( Fig. 4b ; Supplementary  Fig. 4d ). In addition, T4Δ ply infected mice had higher numbers of neutrophils and monocytes in the BALF ( Supplementary Fig. 4e ).
The enhanced inflammation and higher infiltration of phagocytes were concurrent with the higher clearance of T4Δ ply compared with T4 from the airways of infected mice (Fig. 4c ). Mice pretreated with antibodies to block MRC-1 before infection with T4 had significantly higher levels of TNF-α and IL-12, and lower levels of IL-10 in BALF at 6 h post infection compared with isotype antibody-treated controls ( Fig. 4d ; Supplementary Fig. 4f ). Mice treated with an anti-MRC-1 antibody had 50% lower bacterial counts in the lower airways compared with controls ( Fig. 4e ), and intracellular bacteria did not colocalize with MRC-1 in alveolar macrophages ( Supplementary Fig. 4g ). Importantly, MRC1 −/− mice also had significantly decreased bacterial numbers in the nasopharynx at 7 and 14 days post challenge compared with wild-type mice in a pneumococcal carriage model with strain D39 (Fig. 4f ). In wild-type mice, MRC-1 + macrophages were found to rapidly accumulate in the 
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NaTuRe MICRObIOLOgY nasopharynx following pneumococcal colonization ( Supplementary  Fig. 5a,b ). Similar to mice treated with an anti-MRC-1 antibody, MRC1 −/− mice had higher levels of the pro-inflammatory cytokines TNF-α and IL-6, and lower levels of anti-inflammatory IL-10 and TGF-β in the nasopharynx compared with wild-type mice at 6 h and 1 day post infection ( Supplementary Fig. 5c-f ). 
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MRC-1-mediated phagocytosis is of particular significance in the lungs, as MRC-1 is abundantly expressed by alveolar macrophages. A previous study 27 highlighted the crucial role of the scavenger receptor MARCO in anti-pneumococcal immunity in the nasopharynx and suggested a minimal role for MRC-1. However, the authors in that study used a 100-fold higher infection dose (1 × 10 7 CFU) for colonization compared with our study, and we have previously shown that in contrast to high-density infection, low-density pneumococcal carriage induces immunoregulatory responses characterized by a sustained elevation of nasopharyngeal TGF-β 1, regulatory T cells and MRC-1-expressing macrophages 26 . In the current study, we demonstrate that the infection dose determines the nature of cytokine response to PLY, whereby lower infection doses lead to cytokine inhibition. Hence, our results suggest that the infection dose is critical when studying host responses to pneumococcal infections.
PLY is not a typical adhesin and has previously been considered to be cytosolic and released only following bacterial lysis. However, recent transmission electron microscopy data 28 have shown that pneumolysin can be localized on the surface, suggesting that it can be available for interactions with host receptors. The above data support our discovery that PLY interacts with MRC-1, which is a finding that represents a conceptual change in our current understanding. Our results suggest that the MRC-1-PLY interaction is not mediated by glycan recognition, since MRC-1 also binds to deglycosylated PLY, and the interaction is specifically mediated by C type lectin domains 4-7 of MRC-1 and domain 4 of PLY.
In conclusion, we discovered a significant role for PLY, whereby MRC-1 acts as a receptor for PLY, enabling pneumococci to invade MRC-1-proficient immune cells, including DCs and alveolar macrophages, in the airways, thereby dampening cytokine responses to establish intracellular residency of pneumococci. While MRC-1 has previously been demonstrated to bind pneumococcal capsular polysaccharides 12, 13 , we show here that it can also directly bind to PLY. This is a hitherto unknown survival mechanism for the pneumococcus and has important implications for future vaccine design against infection. The potential mechanisms involved are summarized in Fig. 4g .
Methods
Pneumococcal strains used. The encapsulated S. pneumoniae serotype 4 strain TIGR4 (T4; ATCC BAA-334) as well as its non-encapsulated isogenic mutant T4R and their isogenic PLY-deficient mutants T4∆ ply and T4R∆ ply were used in this study. Clinical isolates of serotype 1 pneumococci expressing non-haemolytic PLY (BHN31 of ST306) and a clonally related strain expressing haemolytic PLY (BHN32 of ST228) were also used 22 . Bacteria were grown on blood agar plates at 37 °C and 5% CO 2 overnight. Colonies were inoculated into C+ Y medium and grown until exponential phase (OD 620 = 0.5). For opsonization, pneumococci were incubated with 5% Type 4 anti-serum for 30 min at 37 °C (Statens Serum Institut).
S. pneumoniae serotype 2, strain D39 (NCTC 7466), was obtained from the National Collection of Type Culture, London, UK. The pneumolysin-deletion D39 mutant D39Δ ply was provided by T. Mitchell (University of Birmingham). Capsular-deficient D39-J (D39Δcps) and the double mutant in PLY and the capsule DKO (double knockout) (D39Δ cpsΔ ply) were provided by L. Hathaway (University of Bern). D39 was cultured on a blood agar base with 5% (v/v) horse blood or in brain heart infusion broth (Oxoid) with 20% (v/v) fetal bovine serum (FBS; Sigma), supplemented with 20 mg ml -1 spectinomycin (Sigma) for the DKO strain.
PLY.
Recombinant PLY, mutant (PdB) or PLY domains (D1-3, D4) were expressed in Escherichia coli and purified as previously described 7 . PLY D1-3 and D4 were provided by T. Mitchell (University of Birmingham). Haemolytic activity of PLY was 100,000 haemolytic units per mg. Purified toxin was passed six times through an endotoxin removal column (Profos), and the absence of detectable lipopolysaccharides was confirmed using a PyroGene Recombinant Factor C assay (Lonza; detection limit 0.01 endotoxin units per ml).
Cell isolation from buffy coats, cell culture and infection. Monocytes were purified from buffy coats of healthy donors (Karolinska University Hospital and Uppsala University Hospital) using a RosetteSep monocyte purification kit (Stem Cell Technologies) and Ficoll-Paque Plus (GE Healthcare) gradient centrifugation.
For differentiation into DCs, monocytes were cultured in R10 (RPMI 1640, 2 mM L-glutamine, 10% FBS) supplemented with GM-CSF (40 ng ml -1 ) and IL-4 (40 ng ml -1 ) from Peprotech for 6 days. DCs were verified by flow cytometry to be > 90% CD1a + CD11c + . In co-culture experiments, at 24 h post infection, DCs were washed and incubated with naive CD4 + T cells in a 1:10 ratio (DCs:T cells) at 37 °C. Supernatants were collected 5 days later for cytokine measurements by ELISA. Cytokine values were subtracted from control wells containing DCs alone. For infection, DCs were incubated with pneumococci at a MOI of 1, and extracellular bacteria were killed using 200 µ g ml -1 gentamicin after 2 h of infection. Cytochalasin D (0.5 mM), wortmannin (0.1 mM) (Sigma) or stattic (5 μ M) (Tocris Biosciences) was added to cells 15 min before pneumococcal infection. In some experiments, DCs were incubated with endotoxin-free PLY at 0.2 μ g ml -1 diluted in R10 medium.
Human monocytic leukemia THP-1 cells (ATCC TIB-202) were cultivated in R10 medium. For differentiation into macrophages, THP-1 cells were treated for 48 h with 20 ng ml -1 of phorbol myristate acetate (Sigma).
Neutrophils were isolated from whole blood following lysis of red blood cells and enriched using an EasySep human neutrophil enrichment kit (Stem Cell Technologies) according to the manufacturer's instructions. Purified neutrophils were verified to be ~99% CD66b + CD16 + . Human naive T cells were purified from fresh peripheral blood mononuclear cells using a EasySep Human Naive CD4 + T Cell Isolation kit (Stem Cell Technologies) and were verified by flow cytometry to be > 95% CD3 + CD4 + . All cells used in this study were mycoplasma tested.
Isolation of mouse BMDMs and culture. Bone marrow cells were flushed from mouse femurs and tibia. Macrophages were grown from bone marrow cells in Dulbecco's modified Eagle's Medium (Sigma) 10% (v/v) fetal calf serum (FCS;
Sigma), penicillin (100 U ml -1 ), streptomycin (100 mg ml -1 ) and L-glutamine (100 mM; Sigma) supplemented with M-CSF (20 ng ml -1 ; R&D Systems). Cultures were maintained in a humidified atmosphere (5% CO 2 ) at 37 °C, and medium was replaced on days 3 and 6. On day 6, cells were plated for use in assays. A total of 6.25 × 10 5 BMDMs were cultured alone (untreated) or infected with D39, D39Δ ply, D39Δ cps or DKO (D39Δ cpsΔ ply) (1 macrophage:10 bacteria) or stimulated with purified PLY (4 μ g ml -1 ). After 24 h of incubation, supernatants were collected and used to assess cytokine production by ELISA or to determine the density of infection by Miles and Misra dilution.
BMDM-T cell co-culture.
Naive CD25 − CD4 + T cells were purified from spleens of C57BL/6 or MRC1 −/− mice by negative selection (Miltenyi Biotec). Non-CD4 + T cells and CD44 + memory T cells were labelled with biotinylated antibodies before the addition of anti-biotin microbeads and magnetic separation. CD4 + T cell purity was > 90%. Purified T cells were added to 24 h pneumococcal-stimulated BMDMs at a ratio of 15:1 for 5 days. Culture supernatants were collected for ELISA, and cells were stained for flow cytometry.
Cell viability assays. Cytotoxicity was determined in the culture supernatants by measuring the release of the enzyme lactate dehydrogenase compared with a 100% lysis control using a Cytotoxicity kit (Roche) according to the manufacturer's instructions.
Real time qPCR. Total cellular RNA was extracted from cells using a RNeasy Kit (Qiagen). The concentration and purity of isolated RNA was determined spectrophotometrically using a Nanodrop ND 1000 spectrophotometer. Complementary DNA was synthesized from the isolated RNA using a High Capacity cDNA Reverse Transcription kit (Applied Biosystems). The qPCR was performed using iTaq Universal SYBR Green Supermix (Bio-Rad) according to the manufacturer's instructions. The following primers were used: Hs_SOCS1_1_SG, Hs_MRC1_1_SG and Hs_GAPDH_1_SG. Each primer pair was validated for specificity by performing a melt curve analysis of the PCR product to ensure the absence of primer dimers and nonspecific products. The mRNA expression level was normalized to the level of GAPDH, and relative expression was determined using the Δ Δ CT method. The TLR Signaling qPCR array (Qiagen) was performed according to the manufacturer's instructions and analysed using the GeneGlobe Data analysis Center (Qiagen).
Mouse experiments and isolation of alveolar macrophages. All mice experiments
were performed in accordance with the local ethics committee (Stockholms Norra djurförsöksetiska nämnd). Male wild-type C57BL/6J mice (6-7 weeks old) were used. Experiments with MRC1 −/− mice were performed at the University of Liverpool with the approval of the UK Home Office and the University of Liverpool's ethics committee. MRC1 −/− mice 29 were generated on a mixed 129SvJ and C57BL/6 background, and then backcrossed to the C57BL/6 strain for at least seven generations. Homozygous knockout mice were bred and maintained at the University of Nottingham and were a gift from L. Martinez-Pomares (University of Nottingham). Wild-type and MRC1 −/− mice used for infection were sex and age matched and no more than 12 weeks of age at the start of the experiment. Wild-type and MRC1 −/− mice were randomized independently to time points by technical staff with no role in the study's design. Researchers were blinded to the experimental group until the data analysis stage. Sample size calculations were Letters NaTuRe MICRObIOLOgY determined to give 90% power, alpha = 5%, assuming an expected mean CFU for the wild type of 1,000 CFU per ml and s.d. of 5% (determined from previous studies). The experiments were powered to detect an expected difference between groups of 10%. Pneumococcal nasopharyngeal carriage model. For induction of pneumococcal nasopharyngeal carriage, mice were lightly anaesthetized and 10 μ l of PBS containing 1 × 10 5 CFU D39 was administered into the nostrils. The dose was confirmed by viable count following infection. At pre-chosen time intervals following infection, mice were killed and nasopharynx, draining cervical lymph nodes and lungs were collected, passed through a 30-μ m cell strainer or homogenized using an Ultra-Turrax T8 homogenizer (IKA). Bacterial counts were determined from tissue homogenates by viable count on blood agar plates. Invasive pneumococcal disease model. Mice were sedated by inhalation of 4% isofluorane, and 50 µ l of PBS containing 1 × 10 6 CFU of wild-type T4 or the PLY mutant T4∆ ply was administered into the nostrils. To block MRC-1, 20 µ l of 0.1 mg ml -1 monoclonal anti-MRC-1 antibody (Abcam) or isotype matched control (Abcam) was administered intranasally 30 min before infection. Post sacrifice, the lungs were perfused twice with ice-cold PBS containing 1 mM EDTA to collect the BALF. To determine viable bacterial counts, serial dilutions of BALF were plated on blood agar plates followed by colony counting. Aliquots of BALF were frozen at − 80 °C for cytokine quantification by ELISA. To isolate alveolar macrophages, BALF was spun down at 400 g for 7 min at 4 °C, resuspended in R10 medium (RPMI 1640 containing 2 mM L-glutamine and 10% FBS) and plated on coverslips for 1 h to allow cells to attach. Unattached cells were removed by washes with PBS. Macrophages were verified phenotypically by flow cytometry (CD11c + Siglec F + ). The percentage of neutrophils (CD11b high Ly6G high ) and monocytes (CD11b high Ly6C high ) in the BALF was quantified by flow cytometry following gating for viable cells stained using the fixable viable dye eFluor 780 (Thermo Fisher Scientific).
MRC-1 knockdown using siRNA. DCs (6 × 10 6 ) were electroporated with 5 µ M siRNA from Life Technologies against MRC-1 (s53926, s53927, s53928) or scrambled control siRNA (4390843, 4390846) on day 4 of DC differentiation. The cells were electroporated using a Bio-Rad gene pulser (square wave, 500 V, 0.5 ms with a single impulse) and immediately resuspended in fresh R10 medium. The cells were used 48 h after siRNA electroporation. Treatment with siRNA reduced MRC-1 protein expression by ~80% as evaluated by western blotting ( Supplementary Fig. 3A ).
Flow cytometry. Cells were fixed with 4% paraformaldehyde and stained with a mouse anti-MRC-1 antibody (Abcam) and a goat-anti mouse Alexa Fluor 488 secondary antibody (Life Technologies). For intracellular staining, cells were fixed with 4% paraformaldehyde and permeabilized with ice-cold methanol. Cells were stained with phospho-STAT1 (Tyr 701) Alexa Fluor 488 conjugated rabbit antibody (Cell Signaling), rabbit anti-SOCS1 (ab135718) and assessed by flow cytometry using a Gallios Flow Cytometer. In addition, the following antibodies from BioLegend were used in this study: CD3 (100235), CD4 (100405), CD8a (100707), CD11b (101207), CD19 (152403), CD45 (103111), CD69 (104507), CD115 (135523), CD206 (MRC-1) (141707), F4/80 (123107), FOXP3 (126403), GATA3 (653805), Gr-1 (108411), MARCO (Bio-Rad ED31), RORγ t (654301), and T-bet (644809). Antibodies were conjugated to fluorescein isothiocyanate (FITC), phycoerythrin, phycoerythrin-Cy7 or allophycocyanin, and appropriate isotype controls were included in all experiments.
Quantification of cytokines.
For cytokine measurements, cell-free culture supernatants were collected 18 h post infection and frozen at − 20 °C. The levels of human TNF-α , IL-12p70, IL-1β , IFN-γ and IL-4 were measured using an OptEIA ELISA kit (BD Biosciences). The levels of mouse TNF-α , IL-12p70, IL-1β , IL-10 and TGF-β in the mouse BALF was measured using the respective mouse ELISA kits (BD Biosciences).
Enzymatic deglycosylation of PLY. PLY was deglycosylated under native conditions using a Protein Deglycosylation kit (Sigma) following the instructions provided with the kit. Briefly, 10 μ g of recombinant PLY was incubated with 1 μ l each of peptide:N-glycosidase F, O-glycosidase, sialidase A, β -(1-4)-galactosidase and β -N-acetylglucosaminidase in a 50 μ l reaction buffer for 3 days at 37 °C. The extent of deglycosylation was assessed by mobility shifts on SDS-PAGE gels.
Pull-down of PLY-interacting proteins and co-immunoprecipitation with MRC-1. To identify proteins interacting with PLY, pull-down was performed on DC and THP-1 native cell lysates using recombinant PLY as the bait. Cells were lysed with native lysis buffer (Abcam) containing 1× protease inhibitors (Roche) on ice for 15 min. Briefly, lysate corresponding to 0.8 mg protein was precleared by incubating with Protein G-agarose beads (Pierce) for 30 min at 4 °C. Subsequently, the precleared lysate was incubated with 1 μ g PLY (Cusabio) for 1 h at 4 °C and then incubated with Protein G beads conjugated to mouse anti-PLY antibody (Abcam) with gentle rotation overnight at 4 °C. As a control, lysates were incubated with isotype antibody or beads alone to distinguish nonspecific interactions.
The beads were washed three times with PBS, and the bound proteins were eluted by boiling in NuPAGE LDS sample buffer for 5 min at 95 °C. The eluted proteins were identified using mass spectrometry at the Science for Life Laboratory in Uppsala, Sweden. The protein identifications were based on at least two matching peptides of 95% confidence per protein. To confirm the interaction between PLY and MRC-1, western blotting was performed on the eluate. MRC-1 was detected using rabbit anti-human MRC-1 antibody (Abcam) and horseradish peroxidase (HRP)-conjugated secondary goat anti-rabbit antibody (GE Healthcare).
Surface plasmon resonance analysis. Surface plasmon resonance experiments were run on Biacore 3000 and T200 instruments (GE Healthcare) at 25 °C with 10 mM HEPES supplemented with 2 mM CaCl 2 and 0.1% (v/v) Tween 20 as running buffer. Pneumolysin (PLY; Causabio) and mannose receptor C type 1 (MRC-1; R&D Systems) were diluted to 10 μ g ml -1 in 10 mM NaOAc pH 4.5 and immobilized on CM5 chips by amine coupling to immobilization levels of 2,200 and 12,000 RU, respectively. PLY was buffer-exchanged into running buffer using a 3 kDa MWCO Amicon centrifugal filter device prior to injections. Human serum albumin was immobilized at 11,000 RU in a separate flow cell as a negative control. Analytes were injected at 30 μ l min -1 and surfaces were regenerated using 10 mM HCl. Sensorgrams were double referenced using a blank flow cell and a buffer injection. Data for injections of PLY over MRC-1 were fitted to a Langmuir 1:1 interaction using BiaEval 4.1 software and the dissociation equilibrium constant was calculated from average association and dissociation rate constants obtained from three separate dilution series analysed on two different sensor chips. Human serum albumin, bovine serum albumin and trastuzumab (Herceptin) were injected at 1 μ M as negative controls for non-specific binding. The influence of mannose on MRC-1 binding was evaluated by pre-incubating 100 nM of MRC with 0.5 mM D-mannose or D-glucose (Sigma) for 1 h in running buffer before injection of the mixed samples over the PLY immobilized chip.
ELISA to measure MRC-1-PLY binding. Briefly, 96-well flat-bottomed plates (Sigma, UK) were coated overnight with 1.25-10 μ g ml -1 of mannose receptor, fulllength (2534-MR-050) or truncated constructs CTLD4-7-Fc, CR-FNII-CTLD1-3-Fc 30 , a gift from Luisa Martinez-Pomares (University of Nottingham), in the presence or absence of galactose or mannose (Sigma) in coating buffer (15 mM Na 2 CO 3 , 35 mM NaHCO 3 , pH 9.6). Wells were blocked with 200 μ l of 20% (v/v) FBS in PBS for 2 h, and then washed three times with 250 μ l PBS, 0.05% (v/v) Tween 20 (Sigma). A total of 10 μ g ml -1 of PLY, PdB, PLY domains 1-3 or PLY domain 4 was added and incubated at 37 °C for 1 h. Wells were washed again with PBS, and bound proteins were detected using a PLY polyclonal antibody (Abcam ab71811) in blocking buffer. Plates were incubated with anti-rabbit IgG alkaline phosphatase (Abcam, ab6722) in blocking buffer. Bound antibodies were detected using the chromogenic substrate p-nitrophenylphosphate for 30 min. NaOH (1 M) was added to all wells and the absorbance was measured at 405 nm.
To study the specific interaction of MRC-1 with PLY versus capsular polysaccharides, immobilized MRC-1 was incubated with PLY (0-5 μ g ml -1 ) in the presence or absence of 2.5 μ g ml -1 of purified serotype 2 or type 4 capsules (SSI Diagnostica). Bound PLY in the presence or absence of capsule was detected using mouse anti-PLY and anti-mouse IgG-HRP. Binding of the purified capsule to MRC-1 was detected using rabbit anti-capsule and anti-rabbit IgG-HRP. Bound antibodies were detected using the chromogenic substrate tetramethylbenzidine. Phosphoric acid (1 M) was used as the stop solution and absorbance was measured at 450 nm.
Immunofluorescence microscopy. Briefly, cells were fixed with 4% paraformaldehyde buffered in PBS for 10 min. Subsequently, the cells were permeabilized using PBS containing 0.5% Tween 20 for 15 min. To block nonspecific interactions, cells were incubated with 5% FBS in PBS for 1 h. Lysosomes were stained using Lysotracker deep red (Thermo Fisher Scientific) before fixation. Early endosomes were stained using Alexa 647 conjugated anti-EEA-1 (Abcam). PLY was stained using mouse anti-PLY (Abcam) and Alexa 488-goat anti-mouse secondary antibody (Thermo Fisher Scientific). MRC-1 was detected using rabbit anti-MRC-1 (Abcam) and Alexa 555-goat anti-rabbit secondary antibody (Thermo Fisher Scientific). Pneumococci were stained using rabbit anti-pneumococcal anti-serum (Eurogentec) labelled with Alexa 488 using a Zenon Rabbit IgG Labeling kit (Thermo Fisher Scientific). Type 1 clinical strains were stained using anti-serum Type 1 (Statens Serum Institut). Samples were washed twice with PBS between the antibody incubations and mounted on slides using ProLong Diamond antifade reagent containing 4,6-diamidino-2-phenylindole (DAPI; Thermo Fisher Scientific). Images were acquired using a Delta Vision Elite microscope under a × 100 objective (GE Healthcare).
Immunohistochemistry. Draining cervical lymph nodes were snap-frozen in liquid nitrogen, and 7-μ m sections were cut. Staining was performed using fluorochrome conjugated MRC-1 (biotin 647, BD Biosciences) and appropriate isotype-matched controls. Sections were mounted in ProLong Gold (Invitrogen) and images were taken using a Zeiss Axioplan LSM 510 confocal microscope as single optical slices of between 0.8 and 1.0 μ m. Images were analysed using Zeiss LSM image browsing software v.4.
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Experimental design 1. Sample size
Describe how sample size was determined.
Each experiment was usually performed thrice. The sample size was chosen in order to achieve statistical significance. The exact number of samples (donors/mice) for the individual experiments are mentioned in the figure legends.
Data exclusions
Describe any data exclusions.
Data were generally not excluded
Replication
Describe the measures taken to verify the reproducibility of the experimental findings.
Experiments were repeated using different human donors and mice to check for reproducibility. Attempts at replication were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Mice were randomly assigned to the experimental groups.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
No blinding was done but the major findings were also independently verified to be consistent by our collaborators in this study. Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
Test values indicating whether an effect is present
Provide confidence intervals or give results of significance tests (e.g. P values) as exact values whenever appropriate and with effect sizes noted.
A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars in all relevant figure captions (with explicit mention of central tendency and variation)
See the web collection on statistics for biologists for further resources and guidance.
